scholarly journals Current Status of Vaccines for Schistosomiasis

2008 ◽  
Vol 21 (1) ◽  
pp. 225-242 ◽  
Author(s):  
Donald P. McManus ◽  
Alex Loukas
Keyword(s):  
Protective Immunity ◽  
Helminth Infection ◽  
Vaccine Development ◽  
Current Control ◽  
Current Status ◽  
Parasite Resistance ◽  
Schistosome Infection ◽  
Control Programs ◽  
Blood Flukes ◽  
Immune Attack

SUMMARY Schistosomiasis, caused by trematode blood flukes of the genus Schistosoma, is recognized as the most important human helminth infection in terms of morbidity and mortality. Infection follows direct contact with freshwater harboring free-swimming larval (cercaria) forms of the parasite. Despite the existence of the highly effective antischistosome drug praziquantel (PZQ), schistosomiasis is spreading into new areas, and although it is the cornerstone of current control programs, PZQ chemotherapy does have limitations. In particular, mass treatment does not prevent reinfection. Furthermore, there is increasing concern about the development of parasite resistance to PZQ. Consequently, vaccine strategies represent an essential component for the future control of schistosomiasis as an adjunct to chemotherapy. An improved understanding of the immune response to schistosome infection, both in animal models and in humans, suggests that development of a vaccine may be possible. This review considers aspects of antischistosome protective immunity that are important in the context of vaccine development. The current status in the development of vaccines against the African (Schistosoma mansoni and S. haematobium) and Asian (S. japonicum) schistosomes is then discussed, as are new approaches that may improve the efficacy of available vaccines and aid in the identification of new targets for immune attack.

scholarly journals Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities

2021 ◽  
Vol 12 ◽  
Author(s):  
Victor Vaernewyck ◽  
Boaz Arzi ◽  
Niek N. Sanders ◽  
Eric Cox ◽  
Bert Devriendt
Keyword(s):  
Inflammatory Response ◽  
Oral Cavity ◽  
Periodontal Disease ◽  
Disease Control ◽  
Dental Plaque ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Current Status ◽  
Tissue Destruction ◽  
Mucosal Vaccination

Approximately 9 out of 10 adults have some form of periodontal disease, an infection-induced inflammatory disease of the tooth-supporting tissues. The initial form, gingivitis, often remains asymptomatic, but this can evolve into periodontitis, which is typically associated with halitosis, oral pain or discomfort, and tooth loss. Furthermore, periodontitis may contribute to systemic disorders like cardiovascular disease and type 2 diabetes mellitus. Control options remain nonspecific, time-consuming, and costly; largely relying on the removal of dental plaque and calculus by mechanical debridement. However, while dental plaque bacteria trigger periodontal disease, it is the host-specific inflammatory response that acts as main driver of tissue destruction and disease progression. Therefore, periodontal disease control should aim to alter the host’s inflammatory response as well as to reduce the bacterial triggers. Vaccines may provide a potent adjunct to mechanical debridement for periodontal disease prevention and treatment. However, the immunopathogenic complexity and polymicrobial aspect of PD appear to complicate the development of periodontal vaccines. Moreover, a successful periodontal vaccine should induce protective immunity in the oral cavity, which proves difficult with traditional vaccination methods. Recent advances in mucosal vaccination may bridge the gap in periodontal vaccine development. In this review, we offer a comprehensive overview of mucosal vaccination strategies to induce protective immunity in the oral cavity for periodontal disease control. Furthermore, we highlight the need for additional research with appropriate and clinically relevant animal models. Finally, we discuss several opportunities in periodontal vaccine development such as multivalency, vaccine formulations, and delivery systems.

Shigella Vaccine Development: Prospective Animal Models and Current Status

2014 ◽  
Vol 14 (10) ◽  
pp. 903-912 ◽  
Author(s):  
Yeon-Jeong Kim ◽  
Sang-Gu Yeo ◽  
Jae-Hak Park ◽  
Hyun-Jeong Ko
Keyword(s):  
Animal Models ◽  
Vaccine Development ◽  
Current Status

scholarly journals Mosquito Control Priorities in Florida—Survey Results from Florida Mosquito Control Districts

Pathogens ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 947
Author(s):  
Rishi Kondapaneni ◽  
Ashley N. Malcolm ◽  
Brian M. Vazquez ◽  
Eric Zeng ◽  
Tse-Yu Chen ◽  
...  
Keyword(s):  
State Government ◽  
Mosquito Control ◽  
Control Strategies ◽  
Mosquito Species ◽  
Research Priorities ◽  
Current Control ◽  
Control Programs ◽  
Common Control ◽  
Surveillance Programs ◽  
Research Questions

Florida lies within a subtropical region where the climate allows diverse mosquito species including invasive species to thrive year-round. As of 2021, there are currently 66 state-approved Florida Mosquito Control Districts, which are major stakeholders for Florida public universities engaged in mosquito research. Florida is one of the few states with extensive organized mosquito control programs. The Florida State Government and Florida Mosquito Control Districts have long histories of collaboration with research institutions. During fall 2020, we carried out a survey to collect baseline data on the current control priorities from Florida Mosquito Control Districts relating to (1) priority control species, (2) common adult and larval control methods, and (3) major research questions to address that will improve their control and surveillance programs. The survey data showed that a total of 17 distinct mosquito species were considered to be priority control targets, with many of these species being understudied. The most common control approaches included truck-mounted ultra-low-volume adulticiding and biopesticide-based larviciding. The districts held interest in diverse research questions, with many prioritizing studies on basic science questions to help develop evidence-based control strategies. Our data highlight the fact that mosquito control approaches and priorities differ greatly between districts and provide an important point of comparison for other regions investing in mosquito control, particularly those with similar ecological settings, and great diversity of potential mosquito vectors, such as in Florida. Our findings highlight a need for greater alignment of research priorities between mosquito control and mosquito research. In particular, we note a need to prioritize filling knowledge gaps relating to understudied mosquito species that have been implicated in arbovirus transmission.

scholarly journals Leishmaniasis: Current Status of Vaccine Development

2001 ◽  
Vol 14 (2) ◽  
pp. 229-243 ◽  
Author(s):  
Emanuela Handman
Keyword(s):  
Dna Sequences ◽  
Vaccine Development ◽  
Development Program ◽  
Skin Lesions ◽  
Mononuclear Phagocytes ◽  
Control Measures ◽  
Host Susceptibility ◽  
Current Status ◽  
Dna Encoding ◽  
And Control

SUMMARY Leishmaniae are obligatory intracellular protozoa in mononuclear phagocytes. They cause a spectrum of diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral disease. Worldwide, there are 2 million new cases each year and 1/10 of the world's population is at risk of infection. To date, there are no vaccines against leishmaniasis and control measures rely on chemotherapy to alleviate disease and on vector control to reduce transmission. However, a major vaccine development program aimed initially at cutaneous leishmaniasis is under way. Studies in animal models and humans are evaluating the potential of genetically modified live attenuated vaccines, as well as a variety of recombinant antigens or the DNA encoding them. The program also focuses on new adjuvants, including cytokines, and delivery systems to target the T helper type 1 immune responses required for the elimination of this intracellular organism. The availability, in the near future, of the DNA sequences of the human and Leishmania genomes will extend the vaccine program. New vaccine candidates such as parasite virulence factors will be identified. Host susceptibility genes will be mapped to allow the vaccine to be targeted to the population most in need of protection.

scholarly journals Cutting Edge: The BTLA–HVEM Regulatory Pathway Interferes with Protective Immunity to Intestinal Helminth Infection

2015 ◽  
Vol 194 (4) ◽  
pp. 1413-1416 ◽  
Author(s):  
Minka Breloer ◽  
Wiebke Hartmann ◽  
Birte Blankenhaus ◽  
Marie-Luise Eschbach ◽  
Klaus Pfeffer ◽  
...  
Keyword(s):  
Protective Immunity ◽  
Helminth Infection ◽  
Cutting Edge ◽  
Intestinal Helminth ◽  
Regulatory Pathway

scholarly journals Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends

2018 ◽  
Vol 18 (15) ◽  
pp. 1304-1323 ◽  
Author(s):  
Roberto Sánchez-Sánchez ◽  
Patricia Vázquez ◽  
Ignacio Ferre ◽  
Luis Miguel Ortega-Mora
Keyword(s):  
Vaccine Development ◽  
Neospora Caninum ◽  
Treatment Options ◽  
Small Ruminants ◽  
Additional Treatment ◽  
Current Status ◽  
Caninum Infection ◽  
Zoonotic Parasites ◽  
Toxoplasma Gondii Infection

Toxoplasmosis and neosporosis are closely related protozoan diseases that lead to important economic impacts in farm ruminants. Toxoplasma gondii infection mainly causes reproductive failure in small ruminants and is a widespread zoonosis, whereas Neospora caninum infection is one of the most important causes of abortion in cattle worldwide. Vaccination has been considered the most economic measure for controlling these diseases. However, despite vaccine development efforts, only a liveattenuated T. gondii vaccine has been licensed for veterinary use, and no promising vaccines against neosporosis have been developed; therefore, vaccine development remains a key goal. Additionally, drug therapy could be a valuable strategy for disease control in farm ruminants, as several drugs that limit T. gondii and N. caninum proliferation and dissemination have been evaluated. This approach may also be relevant to performing an initial drug screening for potential human therapy for zoonotic parasites. Treatments can be applied against infections in adult ruminants to minimize the outcomes of a primo-infection or the reactivation of a chronic infection during gestation or in newborn ruminants to avoid infection chronification. In this review, the current status of drug development against toxoplasmosis and neosporosis in farm ruminants is presented, and in an effort to promote additional treatment options, prospective drugs that have shown efficacy in vitro and in laboratory animal models of toxoplasmosis and neosporosis are examined.

scholarly journals Overview of Plant-Derived Vaccine Antigens: Dengue Virus

2011 ◽  
Vol 14 (3) ◽  
pp. 400 ◽  
Author(s):  
Ravindra B Malabadi ◽  
Advaita Ganguly ◽  
Jaime A Teixeira da Silva ◽  
Archana Parashar ◽  
Mavanur R Suresh ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Dengue Virus ◽  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Low Cost ◽  
Current Status ◽  
Human Immune Deficiency Virus ◽  
Dengue Vaccine ◽  
New Methods ◽  
Vaccine Antigens

ABSTRACT - This review highlights the advantages and current status of plant-derived vaccine development with special reference to the dengue virus. There are numerous problems involved in dengue vaccine development, and there is no vaccine against all four dengue serotypes. Dengue vaccine development using traditional approaches has not been satisfactory in terms of inducing neutralizing antibodies. Recently, these issues were addressed by showing a very good response to inducing neutralizing antibodies by plant-derived dengue vaccine antigens. This indicates the feasibility of using plant-derived vaccine antigens as a low-cost method to combat dengue and other infectious diseases. The application of new methods and strategies such as dendritic cell targeting in cancer therapy, severe acute respiratory syndrome, tuberculosis, human immune deficiency virus, and malaria might play an important role. These new methods are more efficient than traditional protocols. It is expected that in the near future, plant-derived vaccine antigens or antibodies will play an important role in the control of human infectious diseases. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Current status of Ebolavirus vaccine development

Pathology ◽  
2016 ◽  
Vol 48 ◽  
pp. S52-S53 ◽  
Author(s):  
Michael D. Nissen
Keyword(s):  
Vaccine Development ◽  
Current Status

The Current Status of Norovirus Vaccine Development

Norovirus ◽  
2019 ◽  
pp. 189-242
Author(s):  
Nada M. Melhem ◽  
Farouk F. Abou Hassan ◽  
Mohammad Ramadan
Keyword(s):  
Vaccine Development ◽  
Current Status

scholarly journals Susceptibility Status of Aedes aegypti L. Against Different Classes of Insecticides in New Delhi, India to Formulate Mosquito Control Strategy in Fields

2018 ◽  
Vol 6 (1) ◽  
pp. 52-62 ◽  
Author(s):  
Roopa Rani Samal ◽  
Sarita Kumar
Keyword(s):  
Secondary Metabolites ◽  
Aedes Aegypti ◽  
Control Strategy ◽  
Mosquito Control ◽  
Current Status ◽  
New Delhi ◽  
Probit Regression ◽  
Statistical Parameters ◽  
Insecticide Susceptibility ◽  
Control Programs

Background: Mosquito control is a major concern throughout the world because of rising cases of mosquito-borne diseases. The outbreak of Zika, Dengue and Chikungunya has caused grave situations raising urgent need to control Aedes aegypti. Moreover, extensive use of synthetic insecticides in mosquito control programs has resulted in high levels of insecticide resistance leading to the use of magnified concentrations, impacting human health and environment adversely. The knowledge about current status of the insecticide susceptibility against Ae. aegypti could help to devise mosquito control strategy. Objective: Present study evaluates the larvicidal potential of thirteen insecticides belonging to seven different classes; organochlorines, organophosphates, carbamates, pyrethroids, neonicotinoids, avermectins and secondary metabolites; against early fourth instars of Ae. aegypti. Materials and Methods: The insecticide susceptibility was evaluated as per WHO protocol. Fatality counts were made after 24h of exposure; and the LC50, LC90 and other statistical parameters were computed by probit-regression analysis. Results: The data reveals the maximum efficacy of pyrethroids and fenitrothion, with lethal values less than 0.001 ppm. Avermectins, organochlorines and carbamates were moderately toxic, while neonicotinoid posed appreciable toxicity. In contrast, berberine, a secondary plant metabolite was found inefficient. The larvicidal efficacy of tested insecticides against Ae. aegypti was found in the decreasing order of pyrethroids > organophosphates > avermectins > organochlorines > carbamates > neonicotinoids > secondary metabolites. Conclusion: Present investigations explore various toxicants as Dengue vector control agents in order to devise a suitable control strategy for mosquito control in fields.

Sign in / Sign up

Export Citation Format

Share Document